CanniMed Therapeutics Inc. completed its initial public offering (IPO) on December 29, 2016, issuing 5 million common shares at a price of $12.00 per common share for gross proceeds of $60 million.
CanniMed Therapeutics commenced trading on the Toronto Stock Exchange under the symbol “CMED”.
Golden Opportunities Fund Inc. (GOF), a retail fund managed by Westcap Mgt and the single largest shareholder of CanniMed, holds 3,684,128 shares representing approximately 18.57% of the issued and outstanding common shares of CanniMed on a non-diluted basis, 29,092 warrants exercisable into 29,092 common shares at a price of $5.50 per share and $1,620,000 debentures convertible into 294,544 shares of CanniMed at a price of $5.50 per share.
The value of GOF holdings in CanniMed is approximately $46.3 million based on the IPO share price, representing 6.8 times of its investment costs.
CanniMed stock closed at $10.75 on December 30, 2016.
photo credit: CanniMed
Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.
Latest posts by Ted Liu (see all)
- Bloom Burton, Innovacorp backed Appili to go public on TSX Venture - March 26, 2019
- Renewal Funds holds 2nd close for fourth fund - March 26, 2019
- Brookfield acquires stake in TransAlta’s Alberta Hydro Assets for $750M - March 25, 2019